// App-Quantinova.ai

PB1153 : Interim Analysis from B-MORE, a 24-month Prospective, Multicentre, Non-interventional Study on Effectiveness and Usage of Recombinant Factor IX Fc (rFIXFc) in Haemophilia B

Researchers

Presenter

  • H. Glosli

Principal Investigators

  • S. Ranta

  • D. Allsup

  • I. Ricca

  • M. Saleh

  • A. Falk

  • E. Santagostino

Medical Centers

  • Oslo University Hospital, Oslo, Norway

  • Karolinska University Hospital, Stockholm, Stockholms Lan, Sweden

  • Hull University Teaching Hospital Trust And Centre for Atherothrombosis and Metabolic Disease, Hull, England, United Kingdom

  • A.O.U. Citta della Salute e della Scienza di Torino, Torino, Italy

  • King Faisal Hospital and Research Centre Riyadh, Riyadh, Saudi Arabia

  • Swedish Orphan Biovitrum AB, Stockholm, Stockholms Lan, Sweden

  • Sobi, Stockholm, Stockholms Lan, Sweden

Locations

  • Norway

  • Sweden

  • United Kingdom

  • Italy

  • Saudi Arabia

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Hemophilia

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Non Interventional

  • Multicenteric

  • Prospective

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved